Q3 FY26: Standalone net loss of Rs 6.97 cr; 9M PAT up sharply to Rs 17 cr

Revenue DeclinePat Growth 25pctPat NegativeEbitda Margin ExpansionResults View source PDF Explain this filing

SHREDIGCEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.7%Reaction day

₹76.00

prior close

₹75.67

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.8%-4.9% vs market

Cement & Cement Products peers, median of 34sector-0.4%-5.2% vs sector

On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 5.2 pts less than its Cement & Cement Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-3.6

15m

-5.5

30m

-3.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.7-0.8-4.9-0.4-5.2

Next day

-6.4+1.8-8.2+1.8-8.2

-5.3+2.8-8.1+1.4-6.6

-7.1+2.3-9.3+0.9-8.0

-7.2+1.8-8.9+0.2-7.4

-9.2+0.3-9.4-1.9-7.3

-5.9+0.5-6.4-1.8-4.1

15d

-6.7-2.5-4.2-5.4-1.3

-13.8-6.3-7.5-9.5-4.3

-10.7-8.0-2.8-13.7+3.0

-1.1+8.3-9.4-5.4+4.2

UpDownMarket · Nifty Microcap 250Sector · Cement & Cement Products peers, median of 34Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q3 FY26 standalone revenue at Rs 183.34 cr (vs Rs 186.76 cr YoY, a decline). Net loss widened to Rs 6.97 cr from Rs 4.84 cr YoY. For 9M FY26, PAT jumped to Rs 17.05 cr from Rs 6.84 cr, a rise of about 149 percent. Finance costs surged to Rs 3.55 cr in Q3 from Rs 0.84 cr. Depreciation also rose. BSR and Co issued an unmodified limited review report on both standalone and consolidated results.

Likely market impact

Quarterly loss widened on higher finance and depreciation costs, but strong nine-month PAT growth and EBITDA margin expansion signal improving full-year outlook.